Madrigal provides update on timeline for topline results from the phase 3 maestro-nafld-1 clinical trial of resmetirom

Company now expects to release topline 52-week results from maestro-nafld-1 in january 2022 company now expects to release topline 52-week results from maestro-nafld-1 in january 2022

MDGL Ratings Summary

MDGL Quant Ranking